Literature DB >> 6604274

Flat revertants isolated from Kirsten sarcoma virus-transformed cells are resistant to the action of specific oncogenes.

M Noda, Z Selinger, E M Scolnick, R H Bassin.   

Abstract

Two flat revertants have been isolated from mutagen-treated populations of Kirsten murine sarcoma virus (Ki-MuSV)-transformed NIH/3T3 cells. These revertants, which appear to be cellular variants resistant to transformation by the Ki-MuSV oncogene v-Ki-ras, contain Ki-MuSV-specific DNA, elevated levels of the v-Ki-ras gene product p21, and rescuable transforming virus. Cell hybridization studies indicated that the revertant phenotype is dominant in hybrids between revertant cells and cells transformed by Ki-MuSV or the closely related Harvey MuSV and BALB MuSV. Analysis of hybrid cells resulting from the fusion of these revertants to cell lines transformed by other retroviruses showed that the action of certain oncogenes structurally unrelated to v-Ki-ras also could be suppressed. Thus, there appear to be functional relationships and diversities among transforming genes (oncogenes) not readily apparent from their structural characteristics.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6604274      PMCID: PMC384306          DOI: 10.1073/pnas.80.18.5602

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  Revertants of an ASV-transformed rat cell line have lost the complete provius or sustained mutations in src.

Authors:  H E Varmus; N Quintrell; J Wyke
Journal:  Virology       Date:  1981-01-15       Impact factor: 3.616

2.  Retroviruses as mutagens: insertion and excision of a nontransforming provirus alter expression of a resident transforming provirus.

Authors:  H E Varmus; N Quintrell; S Ortiz
Journal:  Cell       Date:  1981-07       Impact factor: 41.582

3.  Mechanism of activation of a human oncogene.

Authors:  C J Tabin; S M Bradley; C I Bargmann; R A Weinberg; A G Papageorge; E M Scolnick; R Dhar; D R Lowy; E H Chang
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

4.  Nucleotide sequence of the p21 transforming protein of Harvey murine sarcoma virus.

Authors:  R Dhar; R W Ellis; T Y Shih; S Oroszlan; B Shapiro; J Maizel; D Lowy; E Scolnick
Journal:  Science       Date:  1982-09-03       Impact factor: 47.728

Review 5.  Fewer and fewer oncogenes.

Authors:  R A Weinberg
Journal:  Cell       Date:  1982-08       Impact factor: 41.582

6.  Proposal for naming host cell-derived inserts in retrovirus genomes.

Authors:  J M Coffin; H E Varmus; J M Bishop; M Essex; W D Hardy; G S Martin; N E Rosenberg; E M Scolnick; R A Weinberg; P K Vogt
Journal:  J Virol       Date:  1981-12       Impact factor: 5.103

7.  Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virus.

Authors:  T Y Shih; A G Papageorge; P E Stokes; M O Weeks; E M Scolnick
Journal:  Nature       Date:  1980-10-23       Impact factor: 49.962

8.  Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family.

Authors:  M E Furth; L J Davis; B Fleurdelys; E M Scolnick
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

9.  Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus.

Authors:  E H Chang; M E Furth; E M Scolnick; D R Lowy
Journal:  Nature       Date:  1982-06-10       Impact factor: 49.962

10.  Cellular transforming genes.

Authors:  G M Cooper
Journal:  Science       Date:  1982-08-27       Impact factor: 47.728

View more
  65 in total

1.  Isolation of rsp-1, a novel cDNA capable of suppressing v-Ras transformation.

Authors:  M L Cutler; R H Bassin; L Zanoni; N Talbot
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

2.  Resistance to oncogenic transformation in revertant R1 of human ras-transformed NIH 3T3 cells.

Authors:  N Kuzumaki; Y Ogiso; A Oda; H Fujita; H Suzuki; C Sato; L Müllauer
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

3.  Thioredoxin reductase 1 deficiency enhances selenite toxicity in cancer cells via a thioredoxin-independent mechanism.

Authors:  Ryuta Tobe; Min-Hyuk Yoo; Noelia Fradejas; Bradley A Carlson; Soledad Calvo; Vadim N Gladyshev; Dolph L Hatfield
Journal:  Biochem J       Date:  2012-08-01       Impact factor: 3.857

4.  Interferon-induced revertants of ras-transformed cells: resistance to transformation by specific oncogenes and retransformation by 5-azacytidine.

Authors:  D Samid; D M Flessate; R M Friedman
Journal:  Mol Cell Biol       Date:  1987-06       Impact factor: 4.272

5.  Differential pathways (phospholipase C and phospholipase D) of bradykinin-induced biphasic 1,2-diacylglycerol formation in non-transformed and K-ras-transformed NIH-3T3 fibroblasts. Involvement of intracellular Ca2+ oscillations in phosphatidylcholine breakdown.

Authors:  T Fu; Y Okano; Y Nozawa
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

6.  Isolation of genes specifically expressed in flat revertant cells derived from activated ras-transformed NIH 3T3 cells by treatment with azatyrosine.

Authors:  W J Krzyzosiak; N Shindo-Okada; H Teshima; K Nakajima; S Nishimura
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

7.  Isolation of recessive (mediator-) revertants from NIH 3T3 cells transformed with a c-H-ras oncogene.

Authors:  H Yamada; T Omata-Yamada; N Wakabayashi-Ito; S G Carter; P Lengyel
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

8.  Point mutation of the autophosphorylation site or in the nuclear location signal causes protein kinase A RII beta regulatory subunit to lose its ability to revert transformed fibroblasts.

Authors:  A Budillon; A Cereseto; A Kondrashin; M Nesterova; G Merlo; T Clair; Y S Cho-Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

9.  Tumor suppression involves down-regulation of interleukin 3 expression in hybrids between autocrine mastocytoma and interleukin 3-dependent parental mast cells.

Authors:  I D Diamantis; A P Nair; H H Hirsch; C Moroni
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  Suppression of tumorigenicity with continued expression of the c-Ha-ras oncogene in EJ bladder carcinoma-human fibroblast hybrid cells.

Authors:  A G Geiser; C J Der; C J Marshall; E J Stanbridge
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.